Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 41
1982 24
1983 48
1984 40
1985 61
1986 65
1987 52
1988 62
1989 56
1990 73
1991 94
1992 106
1993 125
1994 134
1995 120
1996 152
1997 135
1998 168
1999 165
2000 151
2001 159
2002 177
2003 199
2004 177
2005 298
2006 418
2007 581
2008 708
2009 719
2010 906
2011 922
2012 744
2013 503
2014 460
2015 456
2016 434
2017 596
2018 597
2019 547
2020 139
Text availability
Article attribute
Article type
Publication date

Search Results

9,217 results
Results by year
Filters applied: . Clear all
Page 1
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem G, et al. Breast Cancer Res Treat 2019 - Review. PMID 31165940 Free PMC article.
BACKGROUND: Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries. ...Cardiac adverse events such as decreased ejection fraction and heart failure have been of particular concern in patients with HER2+ breast cancer. ...
BACKGROUND: Breast cancer is a leading cause of death for women worldwide, with incidence increasing in lower-income countries …
The microbiome and breast cancer: a review.
Chen J, et al. Breast Cancer Res Treat 2019 - Review. PMID 31456069
However, the microbiome associated with normal breast tissue and breast diseases is poorly understood. Collectively, studies have shown that breast tissue has a distinct microbiome with particular species enriched in the breast tissue itself, as well as the nipple aspirate and gut bacteria of women with breast cancer. More importantly, the breast and associated microbiomes may modulate therapeutic response and serve as potential biomarkers for diagnosing and staging breast cancer....
However, the microbiome associated with normal breast tissue and breast diseases is poorly understood. Collectively, studies h …
Social determinants of breast cancer risk, stage, and survival.
Coughlin SS. Breast Cancer Res Treat 2019 - Review. PMID 31270761
Socioeconomic factors influence risk of breast cancer. For all racial/ethnic groups, breast cancer incidence rates tend to be positively associated with socioeconomic status. ...There are well-documented disparities in breast cancer survival by socioeconomic status, race, education, census-tract-level poverty, and access to health insurance and preventive care. ...
Socioeconomic factors influence risk of breast cancer. For all racial/ethnic groups, breast cancer incidence rat …
Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
Korzets Y, et al. Breast Cancer Res Treat 2019 - Review. PMID 30929116
PURPOSE: There is uncertainty about outcomes differences between partial breast irradiation (PBI) and whole breast irradiation (WBI) for early-stage breast cancer. METHODS: Prospective randomized trials comparing adjuvant PBI to WBI in early-stage invasive breast cancer were identified using PubMed. ...
PURPOSE: There is uncertainty about outcomes differences between partial breast irradiation (PBI) and whole breast irradiation …
Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Yeo W, et al. Breast Cancer Res Treat 2019 - Review. PMID 31270763
METHODS: The Asian Breast Cancer Cooperative Group (ABCCG) reviewed current ESO-ESMO and St. Gallen recommendations for treating hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer in premenopausal women. ...CONCLUSION: Premenopausal Asian women with breast cancer have unique disease characteristics and may benefit from treatment that differs somewhat from international guidelines. ...
METHODS: The Asian Breast Cancer Cooperative Group (ABCCG) reviewed current ESO-ESMO and St. Gallen recommendations for treati …
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
Petrelli F, et al. Breast Cancer Res Treat 2019 - Review. PMID 30659432
BACKGROUND: Several trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (BC), in first or subsequent lines of therapy. ...
BACKGROUND: Several trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive (ER+ …
Clinical implications of germline mutations in breast cancer genes: RECQL.
Bowden AR and Tischkowitz M. Breast Cancer Res Treat 2019 - Review. PMID 30610487 Free PMC article.
BACKGROUND: The identification of new hereditary breast cancer genes is an area of highly active research. In 2015, two independent studies provided initial evidence for a novel breast cancer susceptibility gene, RECQL, a DNA helicase which plays an important role in the DNA damage response. ...An Australian case-control study also failed to identify an increased risk of breast cancer associated with RECQL loss of function variants. ...
BACKGROUND: The identification of new hereditary breast cancer genes is an area of highly active research. In 2015, two indepe …
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J, et al. Breast Cancer Res Treat 2019. PMID 30756284
PURPOSE: Following a diagnosis of breast cancer, BRCA mutation carriers face an increased risk of developing a second (contralateral) cancer in the unaffected breast. ...Thus, we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer. ...
PURPOSE: Following a diagnosis of breast cancer, BRCA mutation carriers face an increased risk of developing a second (contral …
Validation of the breast cancer surveillance consortium model of breast cancer risk.
Tice JA, et al. Breast Cancer Res Treat 2019. PMID 30796654
We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed for up to 10 years. METHODS: The BCSC model combines breast density with other risk factors to estimate a woman's 5- and 10-year risk of invasive breast cancer. ...
We assessed the accuracy of the breast cancer surveillance consortium (BCSC) model in a racially diverse population followed f …
Inherited variants in XRCC2 and the risk of breast cancer.
Kluźniak W, et al. Breast Cancer Res Treat 2019. PMID 31463769 Free PMC article.
XRCC2 has been reported to be a breast cancer susceptibility gene and is now included in several breast cancer susceptibility gene panels. ...There is no evidence that this mutation predisposes to breast cancer (and other cancers). It is premature to consider XRCC2 as a breast cancer-predisposing gene....
XRCC2 has been reported to be a breast cancer susceptibility gene and is now included in several breast cancer s …
9,217 results
Jump to page
Feedback